Catalyst Brief

← Calendar

Readoutin 165d

Novartis Pharmaceuticals — Inclisiran sodium 300 mg

Phase 3 primary completion: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease.

Date
May 2027
Type
Readout
Indication
Atherosclerotic Cardiovascular Disease

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Novartis Pharmaceuticals

  1. Apr2027
  2. Mar2027
  3. Feb2027
    Readoutin 76d
    Novartis Pharmaceuticals — everolimus
    Phase 3 primary completion: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment.